Home » Stocks » Acorda Therapeutics

Acorda Therapeutics, Inc. (ACOR)

Stock Price: $0.740 USD -0.023 (-3.07%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $0.720 -0.020 (-2.70%) Aug 7, 7:14 PM

Stock Price Chart

Key Info

Market Cap 35.51M
Revenue (ttm) 159.93M
Net Income (ttm) -231.83M
Shares Out 47.98M
EPS (ttm) -4.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $0.740
Previous Close $0.763
Change ($) -0.023
Change (%) -3.07%
Day's Open 0.758
Day's Range 0.708 - 0.760
Day's Volume 1,900,603
52-Week Range 0.603 - 4.460

More Stats

Market Cap 35.51M
Enterprise Value 159.42M
Earnings Date (est) Oct 22, 2020
Ex-Dividend Date n/a
Shares Outstanding 47.98M
Float 43.11M
EPS (basic) -4.89
EPS (diluted) -4.66
FCF / Share -3.30
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 9.12M
Short Ratio 4.58
Short % of Float 22.69%
Beta 1.58
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 0.22
PB Ratio 0.12
Revenue 159.93M
Operating Income -398.97M
Net Income -231.83M
Free Cash Flow -157.47M
Net Cash -123.92M
Net Cash / Share -2.58
Gross Margin 98.52%
Operating Margin -249.46%
Profit Margin -131.40%
FCF Margin -98.46%
ROA -6.58%
ROE -53.07%
ROIC -39.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 1
Overweight 0
Hold 4
Underweight 0
Sell 1

Analyst Consensus: Hold

Price Target

(251.35% upside)
Current: $0.740
Target: 2.60
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-59.19%-19.86%13.22%5.47%22.71%19.34%10.01%4.65%53%-
Gross Profit158374476411400321270248226155
Operating Income-39993.49-192-17.4845.3038.8230.3725.6035.04-8.42
Net Income-27333.68-223-34.6211.0617.6716.4415530.61-11.77
Shares Outstanding47.5147.0146.0045.2642.2341.1540.2139.4639.0038.36
Earnings Per Share-5.750.71-4.86-0.760.250.420.393.840.76-0.31
EPS Growth-----40.48%7.69%-89.84%405.26%--
Operating Cash Flow-12815197.1429.6538.4874.6539.2952.1266.34-19.22
Capital Expenditures-90.43-33.33-13.69-6.19-5.92-5.08-4.04-10.38-2.19-2.45
Free Cash Flow-21911783.4523.4632.5669.5735.2441.7464.14-21.66
Cash & Equivalents169446307159359309274234296240
Total Debt2503443353312932914.375.396.377.33
Net Cash / Debt-80.67103-27.64-17266.6417.80270229290233
Book Value311612520664603540440386205151
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Acorda Therapeutics, Inc.
Country United States
Employees 344
CEO Ronald Cohen

Stock Information

Ticker Symbol ACOR
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ACOR
IPO Date February 10, 2006


Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease and ARCUS product for the treatment of acute migraine. Further, it develops rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.